Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 6c; Issues Light Q3, FY12 Outlook

Article Stock Quotes (1) Comments (0)

Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q2 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $197 million versus the consensus estimate of $191.51 million.

Medicis Pharmaceutical Corp. sees Q3 2012 EPS of $0.41-$0.58, versus the consensus of $0.78. Medicis Pharmaceutical Corp. sees Q3 2012 revenue of $185-$200 million, versus the consensus of $221.95 million.

Medicis Pharmaceutical Corp. sees FY2012 EPS of $2.25-$2.65, versus the consensus of $2.74. Medicis Pharmaceutical Corp. sees FY2012 revenue of $800-$834 million, versus the consensus of $846.4 million.

Medicis Pharmaceutical Corp. sees Q4 2012 EPS of $0.72-$0.95. Medicis Pharmaceutical Corp. sees Q4 2012 revenue of $216-$235 million.

For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
• salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
• Marvell Technology Group (MRVL) Tops Q1 EPS by 5c; Issues Solid Outlook

Create E-mail Alert Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?